NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03192618,"The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.",https://clinicaltrials.gov/study/NCT03192618,,UNKNOWN,To compare The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy.,NO,Hepatocellular Carcinoma,"PROCEDURE: adjuvant transarterial chemoinfusion (TAI)|DRUG: mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)","Disease-free survival (DFS), disease-free survival, From date of randomization until the date of recurrence, assessed up to 60 months","recurrence rate, recurrence rate, 1 year, 2 year, 3 year, 5 year after surgery|Overall survival (OS), overall survival, From date of randomization until the date of death from any cause, assessed up to 60 months",,Sun Yat-sen University,,ALL,"ADULT, OLDER_ADULT",PHASE3,290,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,B2017-006-01,2017-07-01,2022-12-31,2024-12-31,2017-06-20,,2017-06-20,"Cancer Center of Sun Yat-Sen University, Guangzhou, +86, China",
